2023
Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis
Jeon C, Jang Y, Lee S, Weon S, Park H, Lee S, Oh Y, Choi S, Wang S, Kim T, Sung I, Jo S. Abnormal kynurenine level contributes to the pathological bone features of ankylosing spondylitis. International Immunopharmacology 2023, 118: 110132. PMID: 37023698, DOI: 10.1016/j.intimp.2023.110132.Peer-Reviewed Original ResearchConceptsModified Stoke Ankylosing Spondylitis Spinal ScoreKyn levelsMouse osteoclast precursorsSera levelsAnkylosing spondylitisStoke Ankylosing Spondylitis Spinal ScoreAS groupDisease activity of ASKyn treatmentOsteoclast formationOsteoclast precursorsTRAP-positive osteoclast formationOsteoblast differentiationSystemic bone lossRANKL-mediated osteoclast differentiationBone formationBone mineralizationCell proliferationFeatures of ankylosing spondylitisOsteoclast differentiation markersRANKL-mediated osteoclastogenesisMRNA expression markersActivity of ASAlkaline phosphateKynurenine levels
2018
Regulation of osteoblasts by alkaline phosphatase in ankylosing spondylitis
Jo S, Han J, Lee YL, Yoon S, Lee J, Wang SE, Kim T. Regulation of osteoblasts by alkaline phosphatase in ankylosing spondylitis. International Journal Of Rheumatic Diseases 2018, 22: 252-261. PMID: 30415492, DOI: 10.1111/1756-185x.13419.Peer-Reviewed Original ResearchConceptsHealthy controlsPrimary CTAS patientsAge-matched healthy controlsRheumatoid arthritis patientsAlkaline phosphatase levelsPossible therapeutic targetOsteoblast differentiationAlkaline phosphataseALP activityRunt-related transcription factor 2RA groupArthritis patientsMale patientsPrimary diseaseSpinal ankylosisRegulation of osteoblastSerum ALPPhosphatase levelsTherapeutic targetALP levelsTranscription factor 2Master transcriptional factorPatientsOsteoblastic activityIL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis
Jo S, Wang SE, Lee YL, Kang S, Lee B, Han J, Sung IH, Park YS, Bae SC, Kim TH. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Research & Therapy 2018, 20: 115. PMID: 29880011, PMCID: PMC5992730, DOI: 10.1186/s13075-018-1582-3.Peer-Reviewed Original ResearchConceptsIL-17AJAK2/STAT3Rheumatoid arthritisHealthy controlsExogenous IL-17AIL-12/23 p40Abnormal bone formationNew rational therapiesStimulus-induced increaseALP activityBone tissue samplesPrimary BdCsControl patientsExtensive inflammationAS pathogenesisBony ankylosisP40 levelsSpinal diseaseFacet jointsRational therapySynovial fluidPatientsPrimary bone-derived cellsBone-derived cellsJAK2 inhibitors